Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.8903
-0.0527 (-5.59%)
Apr 16, 2026, 11:36 AM EDT - Market open
Aprea Therapeutics Employees
Aprea Therapeutics had 8 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$35,720
Profits / Employee
-$1,574,946
Market Cap
10.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 0 | - |
| Dec 31, 2024 | 8 | 1 | 14.29% |
| Dec 31, 2023 | 7 | -2 | -22.22% |
| Dec 31, 2022 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| CytoMed Therapeutics | 43 |
| BioLineRx | 24 |
| CalciMedica | 16 |
| Theriva Biologics | 16 |
| NewcelX | 15 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
APRE News
- 15 days ago - Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - GlobeNewsWire
- 17 days ago - Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement - GlobeNewsWire
- 17 days ago - Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - GlobeNewsWire
- 4 weeks ago - Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars - Benzinga
- 2 months ago - Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial - GlobeNewsWire
- 2 months ago - Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - GlobeNewsWire